Abstract:Purpose: Lung adenocarcinoma (LUAD) is a main subtype of lung cancer, which is the leading cause of cancer-related deaths. The five-year survival rates of lung cancer patients are still comparatively low. Therefore, potential therapeutic targets are urgently needed to improve the survival of lung cancer patients. In this study, we identified FAM111B as an oncogene and potential therapeutic target for LUAD. Methods: The TCGA database and tissue microarray analysis were used to compare the expression of FAM111B in tumor tissue and normal tissues and evaluate the relationship between FAM111B expression and clinical survival. FAM111B was knocked down and overexpressed to observe whether FAM111B could affect the proliferation, migration, cell cycle, and apoptosis of LUAD cells in vivo and in vitro. Results: FAM111B was highly expressed in tumor tissues compared with normal tissues (P<0.01). LUAD patients with hyper-expression of FAM111B had a lower recurrence-free survival (P<0.01) and shorter overall survival (P<0.01). Knocking down FAM111B inhibited cell proliferation, migration and invasion in vitro and tumor growth in vivo. Silencing FAM111B could arrest LUAD cells at G2/M phase and increase apoptosis. Overexpression of FAM111B promoted the growth of lung cancer cells. FAM111B was identified as a direct target of p53 in existing researches by chip-seq analysis. Bioinformatics analysis predicted that FAM111B could directly bind to BAG3 (BCL2 associated athanogene 3). When FAM111B was down-regulated, both expression of BAG 3 and BCL2 were significantly reduced, whereas decreasing the expression of BAG3 had no effect on FAM111B. Conclusions: Our study indicated that FAM111B might be an oncogene and potential therapeutic target in LUAD which could be involved in the regulation of tumor cells by p53 signaling pathway and play an important role in the process of cell cycle and apoptosis by influencing the expression of BAG3 and BCL2.

Effect of FAM196B in Human Lung Adenocarcinoma.

FAM111B, a direct target of p53, promotes the malignant process of lung adenocarcinoma.

FAM189A2 plays a tumour suppressor role in lung adenocarcinoma by influencing cell apoptosis, CXCR4 expression and tight junction proteins

FAM117A is a New Prognostic Marker of Lung Adenocarcinoma and Predicts Sensitivity to PD0332991

Pan-cancer analysis and experimental validation reveal FAM72D as a potential novel biomarker and therapeutic target in lung adenocarcinoma

Identifying Immune Cell Infiltration and Effective Diagnostic Biomarkers in Lung Adenocarcinoma by Comprehensive Bioinformatics Analysis and In Vitro Study

Fam72 Serves As A Biomarker Of Poor Prognosis In Human Lung Adenocarcinoma

FAM83B Promotes the Invasion of Primary Lung Adenocarcinoma Via PI3K/AKT/NF-κB Pathway

Overexpression of Family with Sequence Similarity 83, Member A (FAM83A) Predicts Poor Clinical Outcomes in Lung Adenocarcinoma.

Upregulation of FAM83D Promotes Malignant Phenotypes of Lung Adenocarcinoma by Regulating Cell Cycle.

Overexpression of FAM83A is Associated with Poor Prognosis of Lung Adenocarcinoma.

Adenovirus Vector-Mediated FAM176A Overexpression Induces Cell Death in Human H1299 Non-Small Cell Lung Cancer Cells.

FAM111B Expression Accelerates the Malignant Phenotypes of Lung Adenocarcinoma

221 Family with Sequence Similarity 83, Member a Attenuates Aggressive Properties of Cervical Cancer

A Novel Neutrophil Extracellular Traps-Related Lncrna Signature Predicts Prognosis in Patients with Early-Stage Lung Adenocarcinoma

Family with Sequence Similarity 83, Member A (FAM83A) As a Promising Prognostic Biomarker in Lung Squamous Cell Cancer

FAM207BP, a Pseudogene-Derived Lncrna, Facilitates Proliferation, Migration and Invasion of Lung Adenocarcinoma Cells and Acts As an Immune-Related Prognostic Factor

Long non-coding RNA FAM83A antisense RNA 1 (lncRNA FAM83A-AS1) targets microRNA-141-3p to regulate lung adenocarcinoma cell proliferation, migration, invasion, and epithelial-mesenchymal transition progression

FAM83A-AS1 Promotes Tumor Progression Through MET Signaling in Lung Adenocarcinoma

Family with Sequence Similarity 83, Member A (FAM83A) Inhibits Ferroptosis Via the Wnt/β-catenin Pathway in Lung Squamous Cell Cancer

FAM163A, a Positive Regulator of ERK Signaling Pathway, Interacts with 14-3-3β and Promotes Cell Proliferation in Squamous Cell Lung Carcinoma